Market Intelligence, Clinical Progress, and High-Purity Reagents for Neuroendocrine Tumor and Immunotherapy Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CADM1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CADM1 ECD-Fc Recombinant Protein High purity (>95%), Endotoxin Controlled (<1 EU/µg). Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View CADM1 Products |
| Gene Delivery | CADM1 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and cell-based conformation assays. |
View CADM1 Products |
| Benchmark Ab | Anti-CADM1 Recombinant Antibody Recombinant positive control derived from benchmark sequences for assay validation. |
View CADM1 Products |
| Validator | CADM1 siRNA Set Target-specific knockdown verification to confirm assay specificity. |
View CADM1 Products |
| Related Target A | CRTAM Heterophilic binding partner on CD8+ T cells and NK cells; critical for evaluating CADM1-mediated immune modulation. |
View CRTAM Products |
| Related Target B | CADM2 Subfamily homolog; essential for off-target counter-screening to prevent neurotoxicity. |
View CADM2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse evaluation | Human, Mouse, and Cynomolgus CADM1 ortholog proteins available with >95% purity and verified sequence identity. |
| Subfamily counter-screening (CADM2/3/4) | Homolog panel proteins strictly verified by mass spectrometry and theoretical molecular weight. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included for assay calibration. |
| False Positives | Sequence-validated siRNA included for target knockdown and specificity checks. |
Live CADM1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CADM1 therapeutics is intensifying, with major players shifting focus from traditional mAbs to antibody-drug conjugates (ADCs) and bispecific T-cell engagers. As first-generation therapies reach preclinical milestones, the next wave of R&D is targeting CADM1-overexpressing recalcitrant cancers, including small cell lung cancer (SCLC), adult T-cell leukemia/lymphoma (ATL), and malignant mesothelioma.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADC | Academic/Biotech Consortia | SCLC, Mesothelioma | Internalization Assay (Need high-purity, natively glycosylated ECD-Fc) |
| Bispecific / T-Cell Engager | Oncology Biotechs | ATL, Solid Tumors | Heterodimer Validation & CRTAM binding assays (Need Cross-reactive Abs) |
| Monoclonal Antibody | Preclinical Programs | Neuroendocrine Tumors | Selectivity Assay (Need Mutant vs WT CADM family proteins) |